Last reviewed · How we verify

NCT02660372

A Multi-center, Randomized, Observer-blind, Parallel Group, 8-weeks Non-inferiority Clinical Trial to Compare the Efficacy and Safety of Two Brands of Simeticone for Symptomatic Treatment of Functional Dyspepsia in Adults

Completed Phase 3 Last updated 14 December 2016
What this trial tests

Phase 3 trial testing Imonogas in Functional Dyspepsia in 210 participants. Completed in 1 December 2016.

Timeline
1 February 2016
Primary endpoint
1 October 2016
1 December 2016

Quick facts

Lead sponsorJohnson & Johnson Consumer and Personal Products Worldwide
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment210
Start date1 February 2016
Primary completion1 October 2016
Estimated completion1 December 2016
Sites1 location across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Johnson & Johnson Consumer and Personal Products Worldwide — full company profile →

Who can join

18 and older, any sex, with Functional Dyspepsia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The aim of this study is to show non-inferiority of two brands of simeticone in adult patients suffering from functional dyspepsia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Functional Dyspepsia

Currently open trials in the same condition.

Other Johnson & Johnson Consumer and Personal Products Worldwide trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02660372.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing